Table 2. Major trials of postoperative RT for gastric and GEJ cancer.

Trial	Phase	Country	Tumor site	Randomization	N	RT Technique	D2 Dissection Rate	R0 Rate	pCR Rate	OS
CROSS	III	Netherlands	GEJ (24.7%) and Esophageal	Preoperative CRT (41.4 Gy + carbo/taxol)→Sx vs. Sx alone	368	3D-CRT	N/A	92% vs. 69% (p<0.001)	29% (Preoperative CRT)	47% vs. 34% (P=0.003), 5-year
POET	III	Germany	GEJ	Preoperative ChT→CRT (30Gy + cis/etop) vs. Preoperative ChT (PLF)	126	3D-CRT (recommended)	N/A	72% vs. 69.5% (NS)	15.6% vs. 2.0%, p=0.03	47% vs. 26% (P=0.06), 3-year
RTOG 9904	II	USA	Gastric and GEJ	Single-arm; all treated with induction ChT (5-FU/leucovorin/cisplatin)→CRT (45 Gy + 5-FU/taxol)→Sx	49	3D-CRT	50%	77%	26%	72%, 1-year

RT, radiotherapy; GEJ, gastroesophageal junction; N, number; R0, margin-negative resection; pCR, pathological complete response; OS, overall survival; CRT, chemoradiation; carbo/taxol, carboplatin/paclitaxel; Sx, surgery; 3D-CRT, 3-dimensional conformal radiotherapy; ChT, chemotherapy; cis/etop, cisplatin/etoposide; PLF, cisplatin/5-FU/leucovorin; taxol, paclitaxel.